Daré Bioscience readies Sildenafil Cream dispensing in 28 states as Flora Sync LF5 draws early orders
The US women's health company reported Q3 2026 results, saying 503B-pathway dispensing of its sildenafil cream should begin this month, with late-stage data for two candidates due in 2027.
Daré Bioscience reported results for the quarter ended 30 September on 16 November 2026, alongside a corporate update. The company said dispensing of DARE to PLAY Sildenafil Cream is expected to start later this month in 28 states, using the Section 503B compounding pathway.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Dare Bioscience, Inc. ↗
Article written by VigiEye from the official source (Dare Bioscience, Inc.). Claims are the company's own. AI-assisted; check the source before acting.